Ani Pharmaceuticals (ANIP) Inventory Average (2013 - 2026)

Ani Pharmaceuticals (ANIP) has 14 years of Inventory Average data on file, last reported at $143.3 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 4.5% year-over-year to $143.3 million; the trailing twelve-month figure through Mar 2026 stood at $143.3 million (up 4.5% YoY), and the FY2025 full-year result was $139.9 million, up 12.85% from the prior year.
• Inventory Average retreated to $143.3 million in Q1 2026, from $144.8 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $144.8 million in Q4 2025 to a low of $82.4 million in Q1 2022.
• A 5-year average of $118.9 million and a median of $112.5 million in 2024 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average jumped 46.93% in 2022 and advanced 1.66% in 2025, its largest moves.
• Tracing ANIP's Inventory Average over 5 years: stood at $105.3 million in 2022, then grew by 3.37% to $108.9 million in 2023, then surged by 30.78% to $142.4 million in 2024, then gained by 1.66% to $144.8 million in 2025, then fell by 1.04% to $143.3 million in 2026.
• Business Quant data shows ANIP's Inventory Average at $143.3 million in Q1 2026, $144.8 million in Q4 2025, and $142.4 million in Q3 2025.